Tumour heterogeneity and a long-standing paucity of effective therapies other than
chemotherapy have contributed to triple-negative breast cancer (TNBC) being the subtype …

Strategies to therapeutically target the tumor microenvironment (TME) have emerged as a
promising approach for cancer treatment in recent years due to the critical roles of the TME …

As the field of translational 'omics has progressed, refined classifiers at both genomic and
proteomic levels have emerged to decipher the heterogeneity of breast cancer in a clinically …

Talimogene laherparepvec (T-VEC) is an oncolytic virus hypothesized to enhance triple-
negative breast cancer (TNBC) responses to neoadjuvant chemotherapy (NAC). This article …

Immunotherapy, particularly agents targeting the immunoregulatory PD-1/PD-L1 axis,
harnesses the power of the immune system to treat cancer, with unique potential for a …

Simple Summary The tumor microenvironment (TME) in breast cancer plays important roles
in tumor behavior and treatment response, making its pathologic assessment critical for …

Breast cancer cells must avoid intrinsic and extrinsic cell death to relapse following
chemotherapy. Entering senescence enables survival from mitotic catastrophe, apoptosis …

Immune checkpoint therapy in breast cancer remains restricted to triple negative patients,
and long-term clinical benefit is rare. The primary aim of immune checkpoint blockade is to …

Many human cancers manifest the capability to circumvent attack by the adaptive immune
system. In this work, we identified a component of immune evasion that involves frequent up …

Surgical resection continues to be the mainstay treatment for solid cancers even though
chemotherapy and immunotherapy have significantly improved patient overall survival and …